Paolo Gallipoli
Overview
Explore the profile of Paolo Gallipoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah V, Giotopoulos G, Osaki H, Meyerhofer M, Meduri E, Gallego-Crespo A, et al.
Blood
. 2024 Dec;
145(7):748-764.
PMID: 39651888
Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves...
2.
Sanchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jimenez-Pompa A, Gallipoli P, et al.
Leukemia
. 2024 Nov;
39(2):460-472.
PMID: 39537978
Clonal hematopoiesis (CH) is nearly universal in the elderly. The molecular and cellular mechanisms driving CH and the clinical consequences of carrying clonally derived mutant mature blood cells are poorly...
3.
Innes A, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al.
Leukemia
. 2024 Sep;
38(11):2443-2455.
PMID: 39300220
Asciminib is a potent and selective inhibitor of BCR::ABL1, with potential to avoid toxicity resulting from off-target kinase inhibition. Forty-nine patients treated with asciminib under a managed access program in...
4.
Borek W, Nobre L, Pedicona S, Campbell A, Christopher J, Nawaz N, et al.
EBioMedicine
. 2024 Sep;
108:105316.
PMID: 39293215
Background: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3...
5.
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, et al.
Blood Adv
. 2024 Sep;
8(21):5590-5597.
PMID: 39265176
Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after...
6.
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James S, et al.
Leukemia
. 2024 Aug;
38(11):2395-2409.
PMID: 39187579
Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients' outcomes. We identify stearoyl-CoA desaturase (SCD), the key...
7.
Lawson H, Holt-Martyn J, Dembitz V, Kabayama Y, Wang L, Bellani A, et al.
Nat Cancer
. 2024 Apr;
5(6):916-937.
PMID: 38637657
Acute myeloid leukemia (AML) is a largely incurable disease, for which new treatments are urgently needed. While leukemogenesis occurs in the hypoxic bone marrow, the therapeutic tractability of the hypoxia-inducible...
8.
Dembitz V, Durko J, Campos J, James S, Lawson H, Kranc K, et al.
Hemasphere
. 2024 Mar;
8(1):e28.
PMID: 38434525
No abstract available.
9.
Othman J, Tiong I, ONions J, Dennis M, Mokretar K, Ivey A, et al.
Blood
. 2023 Aug;
143(4):336-341.
PMID: 37647641
Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there...
10.
Woodley K, Dillingh L, Giotopoulos G, Madrigal P, Rattigan K, Philippe C, et al.
Nat Commun
. 2023 Apr;
14(1):2132.
PMID: 37059720
Resistance to standard and novel therapies remains the main obstacle to cure in acute myeloid leukaemia (AML) and is often driven by metabolic adaptations which are therapeutically actionable. Here we...